The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Fixed-duration pirtobrutinib plus obinutuzumab shows promise in frontline CLL
Inhye Ahn, MD, Dana-Farber Cancer Institute, Boston, MA, discusses results from a Phase II study (NCT06333262) evaluating fixed-duration pirtobrutinib plus obinutuzumab in previously untreated chronic lymphocytic leukemia (CLL). She reviews the promising response rates, rates of undetectable measurable residual disease (MRD), and favorable cardiovascular safety profile, highlighting the potential of this time-limited combination in the frontline setting. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
